Understanding the role of PTX3 in predicting prognosis in patients with AMI is crucial

Oct 13, 2025 by orovajewels.com 133 views

The Role of Pentraxin-3 as a Predictor of Prognosis in Patients with Acute Myocardial Infarction during Treatment and 30 Days after Treatment at H. Adam Malik Medan Hospital

Introduction

Acute myocardial infarction (AMI) is a serious medical condition that occurs due to atherosclerotic plaque rupture, which is part of the inflammatory process that occurs from the formation of plaque to the occurrence of acute coronary syndrome. In this context, Pentraxin-3 (PTX3) appears as an acute phase glycoprotein produced by hematopoietic and endothelium cells. Research shows that the measured PTX3 levels in the initial phase of myocardial infarction can function as an important prognostic marker for patients. Understanding the role of PTX3 in predicting prognosis in patients with AMI is crucial in improving patient outcomes and reducing mortality rates.

Background

Acute myocardial infarction is a leading cause of morbidity and mortality worldwide. The inflammatory process plays a crucial role in the development of atherosclerosis, which can lead to the rupture of atherosclerotic plaques and subsequent AMI. Pentraxin-3 (PTX3) is an acute phase glycoprotein that is produced by hematopoietic and endothelium cells in response to inflammatory stimuli. PTX3 has been shown to be a sensitive marker of inflammation and has been implicated in the pathogenesis of various inflammatory diseases, including atherosclerosis.

Research Methodology

This study was a prospective cohort study conducted at H. Adam Malik Hospital Medan, involving 87 patients diagnosed with acute myocardial infarction in the period April to September 2019. The study aimed to investigate the relationship between PTX3 levels and the incidence of major cardiovascular events (KKVM) in patients with AMI. The data collected included risk factors for traditional atherosclerosis, clinical presentations, and laboratory results. Serum levels of PTX3 were examined when the patient was accepted in the emergency department. During treatment, all patients were observed to determine the incidence of major cardiovascular (KKVM), which included acute heart failure, cardiogenic shock, arrhythmias, and death. Patients who had been returned will also be followed for 30 days after the care.

Research Result

Of the 87 patients studied, 38 patients (43.7%) experienced KKVM, with heart failure as the most common event, found in 14 patients (16.1%). This study found no significant differences in cardiovascular risk factors between the two groups of patients. However, there is a significant relationship (p <0.001) between PTX3 levels and the KKVM incidence, which was revealed through the Mann-Whitney test. Multivariate logistics regression analysis shows that PTX3 levels independently predict the occurrence of KKVM, with a relative risk value (RR) of 1,388 and 95% confidence interval between 1,142 to 1,686 and P = 0.001. This shows that the higher the level of PTX3, the more likely the occurrence of KKVM.

Discussion

The results of this study showed a significant relationship between PTX3 serum levels and major cardiovascular events, both during hospital nursing or 30 days after the return of patients with acute myocardial infarction. PTX3 levels can be a predictor tool that is useful for identifying high-risk patients, so that further interventions can be done earlier. The evaluation of PTX3 levels is not only beneficial for patient prognosis, but can also improve the quality of medical treatments for those who suffer from acute myocardial infarction.

Conclusion

The implementation of the use of PTX3 as a biomarker in clinical practice will provide better insight to patient management and more favorable long-term results. The role of PTX3 in predicting prognosis in patients with AMI is crucial in improving patient outcomes and reducing mortality rates. Further studies are needed to confirm the findings of this study and to investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.

Recommendations

Based on the findings of this study, the following recommendations are made:

The use of PTX3 as a biomarker in clinical practice should be implemented to provide better insight to patient management and more favorable long-term results.
Further studies are needed to confirm the findings of this study and to investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.
The evaluation of PTX3 levels should be included in the routine assessment of patients with AMI to identify high-risk patients and to provide early interventions.

Limitations

This study had several limitations, including:

The sample size was relatively small, which may have limited the generalizability of the findings.
The study was conducted in a single hospital, which may have introduced selection bias.
The study did not investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.

Future Directions

Future studies should aim to:

Confirm the findings of this study and to investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.
Investigate the potential use of PTX3 as a biomarker in other clinical settings, such as in patients with chronic heart failure or in patients undergoing cardiac surgery.
Develop a more sensitive and specific assay for PTX3 to improve its utility as a biomarker in clinical practice.
Q&A: The Role of Pentraxin-3 as a Predictor of Prognosis in Patients with Acute Myocardial Infarction

Q: What is Pentraxin-3 (PTX3) and how is it related to acute myocardial infarction (AMI)?

A: Pentraxin-3 (PTX3) is an acute phase glycoprotein produced by hematopoietic and endothelium cells in response to inflammatory stimuli. It has been shown to be a sensitive marker of inflammation and has been implicated in the pathogenesis of various inflammatory diseases, including atherosclerosis. In the context of AMI, PTX3 levels have been found to be elevated and have been associated with a poor prognosis.

Q: What is the significance of PTX3 levels in predicting prognosis in patients with AMI?

A: The results of this study showed a significant relationship between PTX3 serum levels and major cardiovascular events, both during hospital nursing or 30 days after the return of patients with acute myocardial infarction. PTX3 levels can be a predictor tool that is useful for identifying high-risk patients, so that further interventions can be done earlier.

Q: How can PTX3 levels be used to predict prognosis in patients with AMI?

A: PTX3 levels can be measured using a sensitive and specific assay. The results of this study showed that PTX3 levels were significantly higher in patients who experienced major cardiovascular events, such as heart failure, cardiogenic shock, arrhythmias, and death. Therefore, PTX3 levels can be used as a biomarker to identify high-risk patients and to provide early interventions.

Q: What are the limitations of this study?

A: This study had several limitations, including:

The sample size was relatively small, which may have limited the generalizability of the findings.
The study was conducted in a single hospital, which may have introduced selection bias.
The study did not investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.

Q: What are the future directions for research on PTX3 as a biomarker in AMI?

A: Future studies should aim to:

Confirm the findings of this study and to investigate the potential use of PTX3 as a biomarker in other inflammatory diseases.
Investigate the potential use of PTX3 as a biomarker in other clinical settings, such as in patients with chronic heart failure or in patients undergoing cardiac surgery.
Develop a more sensitive and specific assay for PTX3 to improve its utility as a biomarker in clinical practice.

Q: What are the implications of this study for clinical practice?

A: The implementation of the use of PTX3 as a biomarker in clinical practice will provide better insight to patient management and more favorable long-term results. PTX3 levels can be used to identify high-risk patients and to provide early interventions, which can improve patient outcomes and reduce mortality rates.

Q: What are the potential applications of PTX3 as a biomarker in other inflammatory diseases?

A: PTX3 has been implicated in the pathogenesis of various inflammatory diseases, including atherosclerosis, rheumatoid arthritis, and sepsis. Therefore, PTX3 may have potential applications as a biomarker in these diseases, which can improve patient outcomes and reduce mortality rates.

Q: What are the future directions for research on PTX3 as a biomarker in other inflammatory diseases?

A: Future studies should aim to:

Investigate the potential use of PTX3 as a biomarker in other inflammatory diseases, such as atherosclerosis, rheumatoid arthritis, and sepsis.
Develop a more sensitive and specific assay for PTX3 to improve its utility as a biomarker in clinical practice.
Investigate the potential mechanisms by which PTX3 is involved in the pathogenesis of inflammatory diseases.